English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduEstimated to become the second leading cause of cancer deaths in the U.S. by 2030, pancreatic cancer has a grim prognosis with nearly 70% of patients facing mortality within the first year of diagnosis. Unfortunately, 40% of small pancreatic cancers elude detection on CT scans until they’ve advanced to an incurable stage.
Tag: Mayo Clinic Comprehensive Cancer Center
Mayo Clinic study reveals proton beam therapy may shorten breast cancer treatment
In a randomized trial, published in The Lancet Oncology, Mayo Clinic Comprehensive Cancer Center researchers uncover evidence supporting a shorter treatment time for breast cancer patients.
Mayo Clinic researchers publish key findings about cell proteins to determine effectiveness of immunotherapy for colon cancer
Mayo Clinic Comprehensive Cancer Center researchers have identified key findings that can assist clinicians in predicting whether a patient with advanced colorectal cancer will benefit from immunotherapy.
Staging pancreatic cancer early with minimally invasive surgery shows positive results in patient prognosis, Mayo Clinic study finds
A study published in the Journal of the American College of Surgeons reveals that performing a minor surgical procedure on patients newly diagnosed with pancreatic cancer helps to identify cancer spread early and determine the stage of cancer.
Mayo Clinic to lead new radiotracer trial for detecting pancreatic cancer
In an academic-industrial collaboration, Mayo Clinic is assessing in a clinical trial a new radiotracer in pancreatic cancer imaging.
Mayo Clinic researchers identify women with twice the risk of cancer in both breasts
Women with cancer in one breast may be at higher risk of developing cancer in the opposite breast if they are carriers of specific genetic changes that predispose them to develop breast cancer, according to a study led by the Mayo Clinic Comprehensive Cancer Center. The findings, published in the Journal of Clinical Oncology, will help personalize approaches to breast cancer screening and risk factors, study authors say.
Mayo Clinic researchers link ovarian cancer to bacteria colonization in microbiome
A specific colonization of microbes in the reproductive tract is commonly found in women with ovarian cancer, according to a new study from Mayo Clinic’s Center for Individualized Medicine. The discovery, published in Scientific Reports, strengthens evidence that the bacterial component of the microbiome — a community of microorganisms that also consists of viruses, yeasts and fungi — is an important indicator for early detection, diagnosis and prognosis of ovarian cancer.
$100 million gift from Fred C. and Katherine B. Andersen Foundation to expand Mayo Clinic’s proton beam therapy services in Minnesota
The Fred C. and Katherine B. Andersen Foundation of Bayport, Minnesota, has made a $100 million multiyear commitment to support the expansion of Mayo Clinic’s proton beam facility in Rochester that will nearly double appointment access for patients in need. In recognition of this gift, Mayo Clinic will name this new facility the Fred C. and Katherine B. Andersen Building.
Research provides critical information about the size and growth speed of gliomas
An important new clue for preventing and treating brain tumors known as gliomas has been identified in research led by the Lunenfeld-Tannenbaum Research Institute (LTRI) at Mount Sinai Hospital in Toronto and Mayo Clinic Comprehensive Cancer Center and Mayo Clinic Center for Individualized Medicine. The study, published in the journal Science, provides a rare window into the biological changes behind glioma development.
Mayo Clinic Researchers ID Potential Gene Marker for Treating Pancreatic Cancer
Researchers at Mayo Clinic Comprehensive Cancer Center have identified a gene marker that may lead to a more effective, precision treatment for pancreatic ductal adenocarcinoma (PDAC). The researcher’s findings are published Nature Cancer.
Mayo Clinic researchers identify drug resistance factors for advanced prostate cancer
In a new study published in Molecular Cancer Research, Mayo Clinic researchers identified critical genomic changes in response to abiraterone acetate/prednisone, a standard treatment option for men with progressive, incurable and castration-resistant prostate cancer.
Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma
A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the research were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago and were published today in the New England Journal of Medicine.
Mayo Clinic Cancer Center Patients, Executive Director Highlighted in American Association for Cancer Research Cancer Disparities Progress Report
The American Association for Cancer Research today released its Cancer Disparities Progress Report 2022. The publication aims to raise awareness of the enormous toll that cancer exacts on racial and ethnic minorities and other diverse and medically underserved populations in the United States while highlighting areas of recent progress in reducing cancer health disparities.